Syros Pharmaceut Stock Price, News & Analysis

Syros Pharmaceuticals (SYRS) announced the grant of a stock option award to Jason Haas, its newly appointed Chief Financial Officer. The Board approved an option to purchase 750,000 shares at an exercise price of $4.54, equivalent to the closing stock price on October 12, 2021. The option has a 10-year term, vesting 25% on the first anniversary of employment, followed by monthly vesting. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a key part of Haas's compensation, aiming to strengthen the company's leadership in gene expression medicines.

Syros Pharmaceuticals (NASDAQ:SYRS) has appointed Jason Haas as Chief Financial Officer, bringing over 25 years of healthcare investment banking experience. CEO Nancy Simonian emphasized Haas's financial, strategic, and leadership expertise, crucial as the company transitions to a commercial-stage entity. Haas previously held senior roles at Barclays, Deutsche Bank, and Goldman Sachs. He expressed excitement about joining Syros during a pivotal time with multiple clinical programs aimed at setting new care standards. The company is focused on delivering innovative gene-controlled therapies.

Syros Pharmaceuticals (NASDAQ:SYRS) has initiated dosing in a confirmatory study for SY-2101, an oral formulation of arsenic trioxide aimed at treating acute promyelocytic leukemia (APL). This study will evaluate pharmacokinetics, safety, and tolerability, laying the groundwork for a planned Phase 3 trial. APL, accounting for about 10% of acute myeloid leukemia cases, has limited treatment options that can be burdensome. Preliminary Phase 1 data for SY-2101 is promising, and the company anticipates filing a New Drug Application by 2024.

Syros Pharmaceuticals (NASDAQ: SYRS) granted an inducement stock option award to its new Chief Commercial Officer, Conley Chee. This award includes options to purchase 360,000 shares at an exercise price of $4.81, aligned with the stock's closing price on September 27, 2021. The options have a 10-year term and will vest over four years, contingent on Mr. Chee's continued employment. This grant aims to attract talent and aligns with Nasdaq Listing Rule 5635(c)(4). Syros is focused on developing innovative gene-expression controlling medicines.

Syros Pharmaceuticals (NASDAQ:SYRS) has appointed Conley Chee as its first Chief Commercial Officer, enhancing its leadership team ahead of critical drug applications expected in 2024. Chee, with 20 years of experience from Novartis, will lead the commercial strategy for the company's late-stage therapies targeting hematologic malignancies. CEO Nancy Simonian emphasized the importance of building a robust commercial organization at this pivotal time. Syros aims to deliver impactful treatments to patients and has a strong pipeline, including drugs for acute myeloid leukemia and blood cancers.

Syros Pharmaceuticals (NASDAQ:SYRS) reported promising new data from the Phase 1 trial of SY-5609, a CDK7 inhibitor, showcasing clinical activity in heavily pre-treated cancer patients. Notably, 28.9% achieved stable disease with tumor regressions, particularly in pancreatic cancer. Syros plans to expand SY-5609's development with trials combining it with chemotherapy and a BTK inhibitor. The company emphasizes a tolerable dosing schedule and supportive preclinical data, aiming for significant opportunities in challenging cancer treatments.

Syros Pharmaceuticals (NASDAQ:SYRS) announced new data from the Phase 1 clinical trial of SY-5609, a potent oral CDK7 inhibitor, at the ESMO Congress 2021. The presentation includes safety and preliminary efficacy results in various cancer types. Additionally, Syros will present preclinical data on SY-5609's antitumor activity in ovarian cancer models and its effects in KRAS-mutant cancers. A conference call is scheduled for September 20, 2021, to discuss these findings, with the oral presentation's abstract embargo lifting on September 17.

Syros Pharmaceuticals (NASDAQ:SYRS) announced the appointment of Dr. Deborah Dunsire to its Board of Directors, bringing over 30 years of life sciences experience. Dr. Dunsire's leadership and expertise in oncology R&D are expected to enhance Syros' growth as it advances its hematology and CDK7 programs. She previously served as CEO of multiple biopharmaceutical companies, including H. Lundbeck A/S and Millennium Pharmaceuticals. Syros aims to develop breakthrough therapies and has a robust clinical pipeline with candidates targeting diseases like acute myeloid leukemia and solid tumors.

Syros Pharmaceuticals (NASDAQ:SYRS) has initiated the dosing of the first patient in the SELECT-AML-1 clinical trial for tamibarotene, a selective RARα agonist, in combination with venetoclax and azacitidine to treat RARA-positive newly diagnosed unfit acute myeloid leukemia (AML) patients. The randomized Phase 2 trial aims to address the need for effective therapies in this patient population, which often does not respond to standard treatments. Promising prior results showed a 67% overall response rate in similar trials, emphasizing the potential of tamibarotene as a valuable treatment option.